Haleon plc (LON:HLN) Given Average Rating of “Hold” by Analysts

Haleon plc (LON:HLN) has been assigned an average recommendation of “Hold” from the six ratings firms that are presently covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is GBX 399.

HLN has been the topic of several research reports. Deutsche Bank Aktiengesellschaft raised their target price on shares of Haleon from GBX 325 to GBX 335 and gave the stock a “sell” rating in a report on Friday, July 31st. JPMorgan Chase & Co. reduced their price target on shares of Haleon from GBX 335 to GBX 315 and set an “underweight” rating for the company in a research report on Thursday, June 25th. Berenberg Bank increased their price objective on shares of Haleon from GBX 512 to GBX 514 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Jefferies Financial Group reissued a “buy” rating and issued a GBX 400 price objective on shares of Haleon in a report on Friday, July 31st. Finally, Royal Bank Of Canada boosted their target price on shares of Haleon from GBX 370 to GBX 390 and gave the company a “sector perform” rating in a research report on Tuesday, August 11th.

Haleon Price Performance

HLN opened at GBX 356.70 on Friday. The company’s 50-day simple moving average is GBX 363.64 and its two-hundred day simple moving average is GBX 359.98. The company has a debt-to-equity ratio of 50.38, a quick ratio of 0.93 and a current ratio of 0.69. The stock has a market capitalization of £31.42 billion, a P/E ratio of 19.71, a P/E/G ratio of 1.49 and a beta of 0.24. Haleon has a 52-week low of GBX 317.80 and a 52-week high of GBX 416.10.

Haleon (LON:HLN) last announced its quarterly earnings results on Thursday, July 30th. The company reported GBX 8.60 EPS for the quarter. Haleon had a net margin of 14.55% and a return on equity of 9.89%. As a group, analysts predict that Haleon will post 19.5033282 EPS for the current year.

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.